## IN THE CLAIMS

Claim 1 (currently amended): Use A use of a solid, semi-solid or liquid formulation of botulinum toxin for the preparation of a medicament intended to treat a disorder characterised by bladder spasms wherein said medicament is for administration without using an injection into the bladder wall.

Claim 2 (currently amended): Use The use according to claim 1, wherein the disorder characterised by bladder spasms is selected from the group consisting of urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor sphincter, urinary retention secondary to spastic sphincter or hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis or characterised by a spasm reflex.

Claim 3 (currently amended): Use The use according to claim 1 or 2, wherein the medicament prepared is in the form of a liquid or semi-solid formulation intended to be administered through infusion into the bladder or a solid, a gel formulation intended to be deposited at the appropriate location of the patient's bladder, a spray formulation intended to be administered through spraying at the appropriate location of the patient's bladder or a solid, semi-solid or liquid botulinum toxin formulation spread on the outer wall of a balloon intended to be inflated inside the bladder.

Claim 4 (currently amended): Use The use according to claim 3, wherein the medicament prepared is a liquid or semi-solid formulation for administration through infusion into the bladder.

Claim 5 (currently amended): Use The use according to claim 4, wherein the liquid or semi-solid formulation has a volume of 20 to 80 ml.

Claim 6 (currently amended): Use The use according to claim 3, wherein the liquid or semi-solid formulation contains from 100 to 2500 units of botulinum toxin type A.

Claim 7 (currently amended): Use The use according to claim 3, wherein the liquid or semi-solid formulation contains from 4,000 to 50,000 units of botulinum toxin type B.

Claim 8 (currently amended): Use The use according to claim 3, wherein the medicament prepared is in the form of a gel formulation.

Claim 9 (currently amended): Use The use according to claim 3, wherein the medicament prepared is in the form of a spray formulation.

Claim 10 (currently amended): Use The use according to claim 3, wherein the medicament prepared is in the form of a solid, semisolid or liquid botulinum toxin formulation spread on the outer wall of a balloon intended to be inflated inside the bladder.

Claim 11 (original): A method of treatment of a disorder characterised by bladder spasms, wherein the disorder characterised by bladder spasms is selected from the group consisting of urinary incontinence due to unstable bladder or unstable detrusor sphincter, voiding complications due to detrusor overactivity or unstable detrusor sphincter, urinary retention secondary to spastic sphincter or hypertrophied bladder neck and neurogenic bladder dysfunction secondary to Parkinson's disease, spinal cord injury, stroke or multiple sclerosis or characterised by a spasm reflex: wherein a patien requiring said treatment is administered with a therapeutically effective dose

of a solid, semi-solid or liquid formulation of botulinum toxin, wherein said formulation is administered without using an injection into the bladder wall.